Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04926779 · ClinicalTrials.gov registry record · NA
Study Utilizing BIOZEK COVID-19 Antigen Rapid Test
A NA study of COVID-19 Testing, sponsored by Mach-E B.V..
- Completed
- Registry status
- NA
- Development phase
- 185
- Enrollment target
- 2
- Study locations
NCT04926779 is a NA study of COVID-19 Testing that has completed, run by Mach-E B.V.. The registered enrollment target is 185 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT04926779, a NA study of COVID-19 Testing, has completed, sponsored by Mach-E B.V..
- COMPLETED
- Registry status
- NA
- Development phase
- 185 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab) on samples that are self-collected; and to perform analysis to compare results. In addition, to obtain RT-PCR test results, performed prior to enrollment, and compare all three results.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Biozek Covid-19 Antigen Rapid Test (Saliva)
Study Locations (2)
New York
- Mobile Covid Services LLC - Flushing
- Quality Research and Invention LLC - Southampton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 185 participants |
| Start Date | 2021-05-24 |
| Est. Completion | 2022-11-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04926779
The ClinicalTrials.gov registry entry for NCT04926779 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 185 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mach-E B.V., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with COVID-19 Testing appearing as the primary indexed condition, and to 1 intervention - of which Biozek Covid-19 Antigen Rapid Test (Saliva) is the first listed.
NCT04926779 reports 2 study locations spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT04926779 about?
NCT04926779 is a clinical study titled "Study Utilizing BIOZEK COVID-19 Antigen Rapid Test". This is a research study to evaluate the Sensitivity and Specificity of BIOZEK COVID-19 Antigen Rapid Test (Saliva) and BIOZEK COVID-19 Antigen Rapid Test (Nasopharyngeal Swab) on samples that are self-collected; and to perform analysis to compare results. In addition, to obtain RT-PCR test results,...
What is the current status of trial NCT04926779?
This trial is currently completed. It is a NA study. The enrollment target is 185 participants. The study started on 2021-05-24. Estimated completion is 2022-11-04.
What conditions does trial NCT04926779 study?
This clinical trial studies the following conditions: COVID-19 Testing.
What interventions are being tested in trial NCT04926779?
The interventions under investigation include: Biozek Covid-19 Antigen Rapid Test (Saliva) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04926779?
This trial is sponsored by Mach-E B.V., which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04926779 being conducted?
This trial has 2 study locations across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for COVID-19 Testing
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.